Author | Takaki, Akinobu| |
---|---|
Published Date | 1994-03-31 |
Publication Title | |
Content Type | Thesis or Dissertation |
JaLCDOI | 10.18926/AMO/52790 |
---|---|
FullText URL | 68_4_243.pdf |
Author | Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Nishina, Sohji| Korenaga, Masaaki| Hino, Keisuke| Fujioka, Shin-ichi| Osawa, Toshiya| Itoshima, Tatsuya| Kawanaka, Miwa| Yamada, Gotaro| Kariyama, Kazuya| Takayama, Hiroki| Kubota, Junichi| Morimoto, Yoichi| Mizushima, Takaaki| Yamashita, Haruhiko| Tanioka, Hiroaki| Negoro, Yuji| Toshimori, Junichi| Kobashi, Haruhiko| Hirano, Atsushi| Itano, Yasuo| Takaki, Akinobu| Yamamoto, Kazuhide| |
Abstract | Hepatitis B virus (HBV) is one of the major viruses causing acute hepatitis. Recently, the incidence of acute hepatitis with genotype A has been increasing in Japan. The aim of this study was to investigate acute hepatitis B (AHB) in Okayama prefecture, with special attention to HBV genotype A. AHB patients who visited one of 12 general hospitals in Okayama prefecture between 2006 and 2010 were retrospectively analyzed. Over the course of the study period, 128 patients were diagnosed with AHB. Sexual transmission was supposed in the majority of patients (78 patients, 61%), including 59 (76%) having sex with heterosexual partners. The genotypes of HBV were assessed in 90 patients (70%), of whom 27 patients were infected with genotype A, 5 with genotype B, and 58 with genotype C. The prevalence of genotype A was significantly higher among male patients (28.7%), aged 20-29 (35.6%, p<0.01), among men who had sex with men (100%, p<0.005), and among patients having sex with unspecified partners (44.8%, p<0.005). Genotype A was not a significant factor associated with delayed HBsAg disappearance. Caution should be exercised with regard to sexually transmissible diseases in order to slow the pandemic spread of AHB due to genotype A. |
Keywords | acute hepatitis hepatitis B virus |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2014-08 |
Volume | volume68 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 243 |
End Page | 247 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2014 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 25145410 |
Web of Science KeyUT | 000340687500006 |
FullText URL | fulltext.pdf |
---|---|
Author | Uchida, Daisuke| Takaki, Akinobu| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Onishi, Hideki| Okada, Hiroyuki| |
Keywords | oxidative stress chronic hepatitis hepatocellular carcinoma |
Published Date | 2020-05-28 |
Publication Title | Nutrients |
Volume | volume12 |
Issue | issue6 |
Publisher | MDPI |
Start Page | 1576 |
ISSN | 2072-6643 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 by the authors. |
File Version | publisher |
PubMed ID | 32481552 |
DOI | 10.3390/nu12061576 |
Web of Science KeyUT | 000554005200001 |
Related Url | isVersionOf https://doi.org/10.3390/nu12061576 |
JaLCDOI | 10.18926/AMO/52898 |
---|---|
FullText URL | 68_5_291.pdf |
Author | Tsuzaki, Ryuichiro| Takaki, Akinobu| Yagi, Takahito| Ikeda, Fusao| Koike, Kazuko| Iwasaki, Yoshiaki| Shiraha, Hidenori| Miyake, Yasuhiro| Sadamori, Hiroshi| Shinoura, Susumu| Umeda, Yuzo| Yoshida, Ryuichi| Nobuoka, Daisuke| Utsumi, Masashi| Nakayama, Eiichi| Fujiwara, Toshiyoshi| Yamamoto, Kazuhide| |
Abstract | It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At>3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect. |
Keywords | interferon gamma ELISPOT assay single nucleotide polymorphisms dendritic cell CD4 T cell |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2014-10 |
Volume | volume68 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 291 |
End Page | 302 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2014 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 25338486 |
Web of Science KeyUT | 000343269300006 |
Related Url | http://ousar.lib.okayama-u.ac.jp/metadata/53129 |
JaLCDOI | 10.18926/AMO/53520 |
---|---|
FullText URL | 69_3_137.pdf |
Author | Seki, Hiroyuki| Ikeda, Fusao| Nanba, Shintaro| Moritou, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Nakamura, Minoru| Yamamoto, Kazuhide| |
Abstract | A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis. |
Keywords | primary biliary cirrhosis keratin 7 hepatic failure |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2015-06 |
Volume | volume69 |
Issue | issue3 |
Publisher | Okayama University Medical School |
Start Page | 137 |
End Page | 144 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 26101189 |
Web of Science KeyUT | 000356903000002 |
JaLCDOI | 10.18926/AMO/53558 |
---|---|
FullText URL | 69_4_219.pdf |
Author | Toshimori, Junichi| Nouso, Kazuhiro| Nakamura, Shinichiro| Wada, Nozomu| Morimoto, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Kuwaki, Kenji| Ohnishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Takaki, Akinobu| Yamamoto, Kazuhide| |
Abstract | We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n=397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing factors for overall recurrence and local recurrence in the context of tumor location and complications were examined. Local recurrence was observed for 113 of the 1,455 nodules. The 1-, 3- and 5-year local recurrence rates were 2.2オ, 7.4オ and 9.5オ, respectively. A multivariate Cox proportional hazard analysis revealed that large tumor size (>2cm), tumor location (adjacent to the major portal branch or hepatic vein), and small ablated margin (<3mm) were independent predisposing factors for local recurrence after RFA (HR=1.70-2.81). Tumor location (adjacent to the major portal branch, hepatic vein, or diaphragm) was also revealed as a risk factor for liver damage due to RFA. HCC adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recurrence and for complications;therefore, special precautions are necessary when applying RFA to HCC near vessels even when the tumors are located at an easy-to-puncture site. |
Keywords | hepatocellular carcinoma radiofrequency ablation ablated margin tumor location |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2015-08 |
Volume | volume69 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 219 |
End Page | 226 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 26289913 |
Web of Science KeyUT | 000365519100005 |
JaLCDOI | 10.18926/AMO/53560 |
---|---|
FullText URL | 69_4_237.pdf |
Author | Nanba, Shintarou| Ikeda, Fusao| Fujioka, Shin-ichi| Araki, Yasuyuki| Takaguchi, Kouichi| Hashimoto, Noriaki| Seki, Hiroyuki| Takaki, Akinobu| Iwasaki, Yoshiaki| Yamamoto, Kazuhide| |
Abstract | The effectiveness of extending treatment duration as response guided therapy was previously reported for chronic hepatitis C (CHC) genotype 1, but is still controversial for genotype 2. The present study is a retrospective cohort study to investigate the effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the timing at which patients obtained undetectable HCV RNA. A total of 306 patients who obtained undetectable HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled. Rapid virological response (RVR) to standard therapy was achieved by 122 patients (51オ), and 89オ of them obtained sustained virological response (SVR), while 69オ of non-RVR patients achieved SVR. Non-RVR patients with undetectable HCV RNA at week 8, and insufficient adherence<80オ pegylated interferon and ribavirin during the first 24 weeks, significantly improved their SVR rate by extended therapy. Among patients receiving extended therapy, drug adherences did not differ between SVR and non-SVR patients, indicating that extending treatment duration might compensate for insufficient antiviral effects due to insufficient drug adherences. This finding might be useful in creating a guideline for extending treatment duration for patients with CHC genotype 2. |
Keywords | hepatitis C virus interferon genotype 2 response-guided therapy |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2015-08 |
Volume | volume69 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 237 |
End Page | 244 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 26289915 |
Web of Science KeyUT | 000365519100007 |
JaLCDOI | 10.18926/AMO/53996 |
---|---|
FullText URL | 70_1_1.pdf |
Author | Yasunaka, Tetsuya| Ikeda, Fusao| Wada, Nozomu| Morimoto, Yuki| Fujioka, Shin-ichi| Toshimori, Junichi| Kobashi, Haruhiko| Kariyama, Kazuya| Morimoto, Yoichi| Takayama, Hiroki| Seno, Tomonori| Takaguchi, Koichi| Moriya, Akio| Miyatake, Hirokazu| Okamoto, Ryoichi| Yabushita, Kazuhisa| Takaki, Akinobu| Yamamoto, Kazuhide| |
Abstract | Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged≥35 years with HBV DNA ≥4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development. |
Keywords | entecavir hepatitis B virus lamivudine hepatocellular carcinoma |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2016-02 |
Volume | volume70 |
Issue | issue1 |
Publisher | Okayama University Medical School |
Start Page | 1 |
End Page | 12 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 26899604 |
Web of Science KeyUT | 000371288700001 |
JaLCDOI | 10.18926/AMO/55435 |
---|---|
FullText URL | 71_5_381.pdf |
Author | Yoshida, Kazuhiro| Umeda, Yuzo| Takaki, Akinobu| Nagasaka, Takeshi| Yoshida, Ryuichi| Nobuoka, Daisuke| Kuise, Takashi| Takagi, Kosei| Yasunaka, Tetsuya| Okada, Hiroyuki| Yagi, Takahito| Fujiwara, Toshiyoshi| |
Abstract | Determining the indications for and timing of liver transplantation (LT) for acute liver failure (ALF) is essential. The King’s College Hospital (KCH) guidelines and Japanese guidelines are used to predict the need for LT and the outcomes in ALF. These guidelines’ accuracy when applied to ALF in different regional and etiological backgrounds may differ. Here we compared the accuracy of new (2010) Japanese guidelines that use a simple scoring system with the 1996 Japanese guidelines and the KCH criteria for living donor liver transplantation (LDLT). We retrospectively analyzed 24 adult ALF patients (18 acute type, 6 sub-acute type) who underwent LDLT in 1998-2009 at our institution. We assessed the accuracies of the 3 guidelines’ criteria for ALF. The overall 1-year survival rate was 87.5%. The new and previous Japanese guidelines were superior to the KCH criteria for accurately predicting LT for acute-type ALF (72% vs. 17%). The new Japanese guidelines could identify 13 acute-type ALF patients for LT, based on the timing of encephalopathy onset. Using the previous Japanese guidelines, although the same 13 acute-type ALF patients (72%) had indications for LT, only 4 patients were indicated at the 1st step, and it took an additional 5 days to decide the indication at the 2nd step in the other 9 cases. Our findings showed that the new Japanese guidelines can predict the indications for LT and provide a reliable alternative to the previous Japanese and KCH guidelines. |
Keywords | living donor liver transplantation acute liver failure fulminant hepatic failure |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2017-10 |
Volume | volume71 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 381 |
End Page | 390 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2017 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 29042695 |
JaLCDOI | 10.18926/AMO/60364 |
---|---|
FullText URL | 74_4_275.pdf |
Author | Muro, Taiko| Nakamura, Shinichiro| Takaki, Akinobu| Onishi, Hideki| Wada, Nozomu| Yasunaka, Tetsuya| Uchida, Daisuke| Oyama, Atsushi| Adachi, Takuya| Shiraha, Hidenori| Okada, Hiroyuki| |
Abstract | Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a promising method for controlling tumors, although it does not entirely eliminate recurrence. Oxidative stress is associated with the progression of hepatocarcinogenesis, while also acting as an anticancer response. The objective of the present study was to investigate the factors influencing post-RFA outcomes. We recruited 235 newly diagnosed HCC patients who received RFA for single tumors. The patients with recurrence were sub-grouped into early and segmental recurrence groups. The characteristics of the sub-grouped patients were evaluated, including by measuring oxidative stress marker reactive oxygen metabolites and antioxidant marker OXY-adsorbent tests. The factors associated with poor survival were a high Child-Pugh score and early recurrence within 2 years in the same segment. The patients who experienced recurrence within 2 years in the same segment showed a larger tumor diameter than did others. According to a multivariate analysis, the OXY values were also significantly low in these patients. In conclusion, maintaining the antioxidant reservoir function with a high OXY value might be necessary to prevent early recurrence within the RFA-treated segment. |
Keywords | oxidative stress hepatocellular carcinoma recurrence, radiofrequency ablation |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2020-08 |
Volume | volume74 |
Issue | issue4 |
Publisher | Okayama University Medical School |
Start Page | 275 |
End Page | 283 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 32843758 |
Web of Science KeyUT | 000562508700002 |
NAID | 120006880203 |
Author | Matsuo, Noriyuki| Shiraha, Hidenori| Fujikawa, Tatsuya| Takaoka, Nobuyuki| Ueda, Naoki| Tanaka, Shigetomi| Nishina, Shinichi| Nakanishi, Yutaka| Uemura, Masayuki| Takaki, Akinobu| Nakamura, Shinichiro| Kobayashi, Yoshiyuki| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide| |
---|---|
Published Date | 2009-07-18 |
Publication Title | BMC Cancer |
Volume | volume9 |
Content Type | Journal Article |
Author | Nakanishi, Yutaka| Shiraha, Hidenori| Nishina, Shin-ichi| Tanaka, Shigetomi| Matsubara, Minoru| Horiguchi, Shigeru| Iwamuro, Masaya| Takaoka, Nobuyuki| Uemura, Masayuki| Kuwaki, Kenji| Hagihara, Hiroaki| Toshimori, Junichi| Ohnishi, Hideki| Takaki, Akinobu| Nakamura, Shinichiro| Kobayashi, Yoshiyuki| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide| |
---|---|
Published Date | 2011-01-04 |
Publication Title | BMC Cancer |
Volume | volume11 |
Content Type | Journal Article |
FullText URL | JGastroenterol_54_11_1019.pdf Table.pdf Figure 1.jpg Figure 2.jpg Figure 3A.tif Figure 3B.tif supplemental figure 1.jpg |
---|---|
Author | Matsumoto, Kazuyuki| Ohara, Toshiaki| Fujisawa, Masayoshi| Takaki, Akinobu| Takahara, Masahiro| Tanaka, Noriyuki| Kato, Hironari| Horiguchi, Shigeru| Yoshida, Ryuichi| Umeda, Yuzo| Fushimi, Soichiro| Yagi, Takahito| Matsukawa, Akihiro| Okada, Hiroyuki| |
Keywords | Immunohistochemistry PD-L1 Pancreatic cancer |
Note | This fulltext will be available in Apr 2020| |
Published Date | 2019-04-29 |
Publication Title | Journal of Gastroenterology |
Volume | volume54 |
Issue | issue11 |
Start Page | 1019 |
End Page | 1028 |
ISSN | 09441174 |
NCID | AA10988015 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
File Version | author |
PubMed ID | 31032528 |
DOI | 10.1007/s00535-019-01586-6 |
Web of Science KeyUT | 000492169400008 |
Related Url | isVersionOf https://doi.org/10.1007/s00535-019-01586-6 |
FullText URL | fulltext.pdf |
---|---|
Author | Yamamoto, Shumpei| Onishi, Hideki| Takaki, Akinobu| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Sakata, Masahiro| Yasunaka, Tetsuya| Shiraha, Hidenori| Okada, Hiroyuki| |
Keywords | Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Low-dose cisplatin plus 5-fluorouracil alpha-Fetoprotein Des-gamma-carboxy prothrombin |
Published Date | 2020-04-21 |
Publication Title | Gastrointestinal Tumors |
Volume | volume7 |
Issue | issue3 |
Publisher | Karger |
Start Page | 83 |
End Page | 92 |
ISSN | 2296-3774 |
NCID | AA12665877 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 The Author(s) |
File Version | publisher |
DOI | 10.1159/000506941 |
Web of Science KeyUT | 000551254300003 |
Related Url | isVersionOf https://doi.org/10.1159/000506941 |
JaLCDOI | 10.18926/AMO/52894 |
---|---|
FullText URL | 68_5_263.pdf |
Author | Namba, Shihoko| Miyake, Kayoko| Ikeda, Fusao| Hazama, Tomoko| Hitobe, Yu| Yamasaki, Noriko| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide| |
Abstract | Nursing support might help patients with chronic hepatitis C (CHC) remain in good mental and physical condition during interferon (IFN) therapy. However, the effects of nursing support have not been studied adequately in this context. This case-control study evaluated the effects of nursing support during IFN therapy. Twenty-four CHC patients who received pegylated IFN and ribavirin were enrolled. Nurses advised patients on the maintenance of their mental and physical condition at weekly visits, based on the results of written questionnaires. An additional 24 patients who received IFN therapy without nursing support and who were matched for age, sex, platelet count, viral serogroup and IFN regimen were selected with propensity score matching as controls. The patients with nursing support during IFN therapy achieved higher sustained virological responses (79%) than those without nursing support (58%). Adherence to the IFN and ribavirin regimens at 24 weeks of therapy were slightly higher in the patients with nursing support than those without it, but these differences were not statistically significant. Adherence to ribavirin after 24 weeks of therapy was significantly higher in those with nursing support than those without it (93% and 66%, p=0.045). These results suggested that nursing support services could contribute to the virological responses of CHC patients by promoting drug-regimen adherence. |
Keywords | chronic hepatitis C nursing support interferon therapy |
Amo Type | Original Article |
Publication Title | Acta Medica Okayama |
Published Date | 2014-10 |
Volume | volume68 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 263 |
End Page | 268 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2014 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 25338482 |
Web of Science KeyUT | 000343269300002 |
Author | Tanaka, Shigetomi| Shiraha, Hidenori| Nakanishi, Yutaka| Nishina, Shin-Ichi| Matsubara, Minoru| Horiguchi, Shigeru| Takaoka, Nobuyuki| Iwamuro, Masaya| Kataoka, Junro| Kuwaki, Kenji| Hagihara, Hiroaki| Toshimori, Junichi| Ohnishi, Hideki| Takaki, Akinobu| Nakamura, Shinichiro| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide| |
---|---|
Published Date | 2012-12-01 |
Publication Title | International Journal of Cancer |
Volume | volume131 |
Issue | issue11 |
Content Type | Journal Article |
FullText URL | fulltext.pdf |
---|---|
Author | Yamamoto, Shumpei| Onishi, Hideki| Oyama, Atsushi| Takaki, Akinobu| Okada, Hiroyuki| |
Keywords | colitis hepatic arterial infusion chemotherapy cisplatin |
Published Date | 2020-01-01 |
Publication Title | Internal Medicine |
Volume | volume59 |
Issue | issue1 |
Publisher | The Japanese Society of Internal Medicine |
Start Page | 69 |
End Page | 75 |
ISSN | 0918-2918 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2020 by The Japanese Society of Internal Medicine |
File Version | publisher |
PubMed ID | 32611959 |
DOI | 10.2169/internalmedicine.3340-19 |
Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.3340-19 |
FullText URL | fulltext.pdf |
---|---|
Author | Adachi, Takuya| Takeuchi, Yasuto| Takaki, Akinobu| Oyama, Atsushi| Wada, Nozomu| Onishi, Hideki| Shiraha, Hidenori| Okada, Hiroyuki| |
Keywords | tolvaptan liver cirrhosis ascites |
Published Date | 2021-05-25 |
Publication Title | International Journal of Molecular Sciences |
Volume | volume22 |
Issue | issue11 |
Publisher | MDPI |
Start Page | 5582 |
ISSN | 1422-0067 |
Content Type | Journal Article |
language | English |
OAI-PMH Set | 岡山大学 |
Copyright Holders | © 2021 by the authors. |
File Version | publisher |
PubMed ID | 34070416 |
NAID | 120007089839 |
DOI | 10.3390/ijms22115582 |
Web of Science KeyUT | 000660134900001 |
Related Url | isVersionOf https://doi.org/10.3390/ijms22115582 |
Author | Nishimura, Mamoru| Takaki, Akinobu| Tamaki, Naofumi| Maruyama, Takayuki| Onishi, Hideki| Kobayashi, Sayo| Nouso, Kazuhiro| Yasunaka, Tetsuya| Koike, Kazuko| Hagihara, Hiroaki| Kuwaki, Kenji| Nakamura, Shinichiro| Ikeda, Fusao| Iwasaki, Yoshiaki| Tomofuji, Takaaki| Morita, Manabu| Yamamoto, Kazuhide| |
---|---|
Published Date | 2013-01-30 |
Publication Title | Hepatology Research |
Volume | volume43 |
Issue | issue10 |
Content Type | Journal Article |
JaLCDOI | 10.18926/AMO/52145 |
---|---|
FullText URL | 68_1_53.pdf |
Author | Terasaka, Tomohiro| Ueta, Eijiro| Ebara, Hirotaka| Waseda, Koichi| Hanayama, Yoshihisa| Takaki, Akinobu| Kawabata, Tomoko| Sugiyama, Hitoshi| Hidan, Ko| Otsuka, Fumio| |
Abstract | A 64-year-old man suffering polyarthralgia and bone pain was referred to our hospital. Renal dysfunction, hypophosphatemia and increased levels of bone alkaline phosphatase were found. The patientʼs serum creatinine level had gradually increased after the initiation of adefovir dipivoxil administration for hepatitis B. In agreement with multifocal uptakes of bone scintigraphy, iliac bone biopsy revealed an abnormal increase in osteoid tissues. Reducing the dose of adefovir and initiating the administration of eldecalcitol were effective for reducing proteinuria and glucosuria, and for ameliorating bone pain with an increase in serum phosphate level. This case first showed a clinical course of hypophosphatemic osteomalacia caused by secondary Fanconiʼs syndrome for 8 years after adefovir administration. Early diagnosis is important for the reversibility of bone damage and for a better renal prognosis. |
Keywords | adefovir dipivoxil (ADV) eldecalcitol Fanconi's syndrome hypophosphatemia osteomalacia |
Amo Type | Case Report |
Publication Title | Acta Medica Okayama |
Published Date | 2014-02 |
Volume | volume68 |
Issue | issue1 |
Publisher | Okayama University Medical School |
Start Page | 53 |
End Page | 56 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2014 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 24553490 |